FEATURES OF THE CLINICAL COURSE OF THYROTOXICOSIS SYNDROME AMONG CARDIAC PATIENTS
Keywords:
thyrotoxicosis syndrome; among cardiac patients; diffuse toxic goiter; immunological marker; amiodarone-induced thyrotoxicosisAbstract
Introduction. Diffuse toxic goiter (DTG) is a disease that is characterized by increased production of thyroid hormones and diffuse enlargement of the thyroid gland, like all autoimmune diseases, it is more common in patients with a positive family history, and usually caused by environmental factors such as stress, smoking, infection, iodine exposure and the postpartum period, and after highly active antiretroviral therapy due to immune reconstitution, which primarily affects the thyroid gland. Relevance. DTG is one of the most common thyroid diseases and is the most important clinically significant thyroid pathology, occurring in 0.5-1.5% of the population. The aim of the study is to determine the frequency of occurrence of diffuse toxic goiter among cardiac patients and to assess its clinical course. Materials and Methods used in order to investigate the research were the collection of clinical materials which were gathered from the clinical research. The research was carried out within 6 months, from January to July 2022, the collection of material was carried out at the Specialized Scientific and Practical Medical Center for Cardiology and Cardiac Surgery of the Aral Sea Region. We consulted 1150 patients who were referred by cardiologists to rule out thyroid diseases. Results and Discussion, out of 1150 patients, 71 patients (6.2%) had diseases occurring with thyrotoxicosis syndrome. While analyzing hormonal and immunological data, DTG was diagnosed in 24 (33.8%) patients. The majority of patients were women - 70.8%. Conclusions. It turned out that many patients with DTG with cardiovascular pathology turn to a cardiologist at the onset of the disease (37.5% of newly diagnosed DTG).
References
Исмаилов С.И., Хайитбоева К.Х. Исследования качества жизни пациентов с диффузно-токсическим зобом// Проблемы биологии и медицины. - 2020. №5. Том. 122. - С. 51-56. DOI: http://doi.org/10.38096/2181-5674.2020.5.00240
Пашенцева Анна Владимировна, & Вербовой А.Ф. (2017). Диффузный токсический зоб. Клиническая медицина, 95 (9), 780-788.
Петунина Н.А. Подходы к лечению функциональных нарушений щитовидной железы // Качество жизни. Медицина. Болезни эндокринной системы. – 2006. – Т. 14. № 3. – С. 22-23.
Трошина Е.А., Свириденко Н.Ю., Ванушко В.Э., Румянцев П.О., Фадеев В.В., Петунина Н.А. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. Проблемы Эндокринологии. 2014;60(6):67-77.
Тухтаев Ж.Кодиркулович, & Хурсанов Ё.Э (2023). Диффузный токсический зоб щитовидной железы. Research Focus, 2 (1), 20-31.
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun;21(6):593-646. doi: 10.1089/thy.2010.0417.
Bobanga ID, McHenry CR. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy. Best Pract Res Clin Endocrinol Metab. 2019 Aug;33(4):101319. doi: 10.1016/j.beem.2019.101319.
Bové KB, Watt T, Vogel A, Hegedüs L, Bjoerner JB, Groenvold M, Bonnema SJ, Rasmussen ÅK, Feldt-Rasmussen U. Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre. Eur Thyroid J. 2014 Sep;3(3):173-8. doi: 10.1159/000365211.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
Fadeyev VV. Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Clinical and experimental thyroidology. 2017;13(3):45-56. doi: 10.14341/ket2017345-56
Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease-real life data. Endocrine. 2017 Jun;56(3):568-578. doi: 10.1007/s12020-017-1306-5.
Ismailov S.I., Khayitboeva K.Kh., Ruzibaev R.Y., Sapaev D.Sh. Health Quality Assessment of Patients with Toxic-Diffuse Goiter. Indian Journal of Forensic Medicine & Toxicology, October-December 2020, Vol. 14, No.4 https://doi.org/10.37506/ijfmt.v14i4.12816
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018 Aug;7(4):167-186. doi: 10.1159/000490384.
Rebecca Bahn et al. Hyperthyroidism and other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinoloigists/ https://journals.aace.com/doi/abs/10.4158/EP.17.3.456
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. doi: 10.1089/thy.2016.0229. Erratum in: Thyroid. 2017 Nov;27(11):1462. PMID: 27521067.
Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016 Oct 20;375(16):1552-1565. doi: 10.1056/NEJMra1510030. PMID: 27797318.
Subekti I, Pramono LA. Current Diagnosis and Management of Graves' Disease. Acta Med Indones. 2018 Apr;50(2):177-182. PMID: 29950539.
Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011;99(1):39–51.
Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris). 2018 Dec;79(6):599-607. doi: 10.1016/j.ando.2018.09.002. Epub 2018 Sep 11. PMID: 30342794.
